GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Apomorphine - ONAPGO continuous subcutaneous infusion

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

ONAPGO / Apomorphine

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
ONAPGO: initial extra dose differs from continuous and later doses

The May 2026 official renal instruction specifically limits the initial extra dose. The older RX rendering supplies PK information without that usable prescribing subsection.

Before applying: Use the complete official product instructions; do not lower every dose automatically or substitute intermittent apomorphine.

Also check: ONAPGO: initial extra dose differs from continuous and later doses

Official source

ONAPGO - official renal prescribing summary

Product / population
ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.
Renal measure
Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.

Renal dosing, restrictions and evidence limits

For mild or moderate renal impairment, the initial extra dose is 0.5-1 mg and must not exceed 1 mg. This renal restriction applies to the initial extra dose: no renal adjustment is needed for the continuous dose, maximum recommended daily dose, or subsequent extra doses. Severe impairment has not been studied. ONAPGO is not substitutable for intermittent apomorphine products. Apply the complete pump training, titration, total-dose, adverse-effect and interaction safeguards; this is not a stand-alone infusion order.

Source revision: Prescribing information revised May 2026; IFU separately revised June 2026. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=f3552b6e-5ae7-4993-aa1a-e399c4a7080a

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

ONAPGO - official renal prescribing summary

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.

Renal method: Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ONAPGO

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Apomorphine - ONAPGO continuous subcutaneous infusion; selected source sections only, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

ONAPGO: initial extra dose differs from continuous and later doses

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

ONAPGO: initial extra dose differs from continuous and later doses

The May 2026 official renal instruction specifically limits the initial extra dose. The older RX rendering supplies PK information without that usable prescribing subsection.

How to use this: Use the complete official product instructions; do not lower every dose automatically or substitute intermittent apomorphine.

GlobalRPh RX List - ONAPGOONAPGO - official renal prescribing summary

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source

ONAPGO - official renal prescribing summary

ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.

Method: Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.

Renal dosing, restrictions and evidence limitsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeONAPGO - official renal prescribing summaryGlobalRPh RX List - ONAPGO
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/onapgo-drug/

Exact product and population

Apomorphine - ONAPGO continuous subcutaneous infusion; selected source sections only, not a complete prescribing monograph.

RDM49-SCOPE-apomorphine-onapgo · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

ONAPGO - official renal prescribing summary

Open original reference

Open / share this exact local source

DailyMed / MDD US Operations, LLC · ONAPGO 98 mg/20 mL (4.9 mg/mL) solution for continuous subcutaneous infusion in adults with advanced Parkinson disease; not an intermittent apomorphine product. Selected renal sections, not a complete pump prescription.

Renal method: Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.
Source date: Prescribing information revised May 2026; IFU separately revised June 2026.
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For mild or moderate renal impairment, the initial extra dose is 0.5-1 mg and must not exceed 1 mg. This renal restriction applies to the initial extra dose: no renal adjustment is needed for the continuous dose, maximum recommended daily dose, or subsequent extra doses. Severe impairment has not been studied. ONAPGO is not substitutable for intermittent apomorphine products. Apply the complete pump training, titration, total-dose, adverse-effect and interaction safeguards; this is not a stand-alone infusion order.

RDM49-official-apomorphine-onapgo-979593b62a-C1 · Source locator: Sections 2.3, 2.5 and 8.6, lines 353-393 and 584-586.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=f3552b6e-5ae7-4993-aa1a-e399c4a7080a
Retrieved
2026-09-09
Exact label title
ONAPGO - official renal prescribing summary
DailyMed Set ID
f3552b6e-5ae7-4993-aa1a-e399c4a7080a
Labeler
MDD US Operations, LLC
Label revision
Prescribing information revised May 2026; IFU separately revised June 2026.
FDA application
NDA214056
Renal-function method
Mild/moderate renal impairment as named in the source; no numerical renal-function cutoff is provided in the selected dosing subsection.
Source date/version
Prescribing information revised May 2026; IFU separately revised June 2026.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
69544d6f00c2f115c5071e2163edbede6e81bb59911cd145adf05244cf84e36a
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ONAPGO

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Apomorphine - ONAPGO continuous subcutaneous infusion; selected source sections only, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Source date: RX page prints February 2025.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

A single-subcutaneous-dose renal PK study found increased apomorphine exposure in moderate impairment; severe impairment was not studied. The retrieved February 2025 RX rendering lacks a usable renal prescribing subsection. This is selected PK content, not the initial-extra-dose rule. A separately stored May 2026 DailyMed label supplies the renal prescribing instructions; it does not repair the RX rendering.

RDM49-rxlist-apomorphine-onapgo-a3cd660637-C1 · Source locator: Clinical Pharmacology: renal impairment, lines 395-397; retrieved dosing section and printed revision.

Source-specific limits

Limited RX rendering. Do not infer dose instructions from exposure changes.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/onapgo-drug/
Retrieved
2026-09-09
Renal-function method
Creatinine clearance (CrCl), mL/min; equation not established in the selected dosing passage.
Source date/version
RX page prints February 2025.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
8e336e95b1cab5fb6c3d0928126c1a186c8c8ac060e53f89a058222f3f0c353a

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/onapgo-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
4b3eee0cf707a34ce69f80ef115e019b9de5985ab70384bc5781dec02bd5ea09
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report